Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer
2期
提前终止
NCT05581589
| 适应症 | Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8 |
|---|
| 分期 | 2期 |
|---|
| 申办方 | University of Washington |
|---|
| 状态 | 提前终止 |
|---|
| 受试者人数 | 4 人 |
|---|
| 干预（药物） | Lymphadenectomy, Radical Cystectomy, Sacituzumab Govitecan |
|---|
| 开始日期 | 2023年6月15日 |
|---|
| 完成日期 | 2024年10月15日 |
|---|
| 结果公布日 | 2026年4月27日 |
|---|
摘要
This phase II trial tests whether sacituzumab govitecan given before radical cystectomy works in treating patients with non-urothelial bladder cancer. Sacituzumab govitecan contains a monoclonal antibody, called sacituzumab, linked to a chemotherapy drug, called govitecan. Sacituzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as TROP2 receptors, and delivers govitecan to kill them. Giving sacituzumab govitecan before radical cystectomy may make the surgery more effective in patients with muscle invasive bladder cancer.
Pathologic Complete Response (pCR Defined as ypT0N0)
At radical cystectomy (Radical cystectomy is expected to occur within 2-6 weeks after the last neoadjuvant trial therapy dose) · Participants
| Treatment (Sacituzumab Govitecan) | 1 Participants |
|---|
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
全部试验
本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。